Psychiatry Decision-Making & Reward Research
Scientists in NYU Langone’s Department of Psychiatry conduct groundbreaking decision-making and reward research. An interdisciplinary team, led by Paul W. Glimcher, PhD, uses different technologies to study decision-making in a range of environments.
Psychiatrists, psychologists, economists, and basic neuroscientists collaborate in the Glimcher Lab to assess decision-making, impulsivity, and the performance of new behavioral tasks in patients with opioid addiction.
They also study behavior in healthy populations using questionnaires, clinical survey work, and competitive and strategic economic games. Studying groups of people allows the team to understand how decision-making evolves in social settings.
The researchers use functional MRI (fMRI) and PET scans in humans to evaluate brain function and study how networks of neurons aggregate in decision-making. We collaborate with researchers at NYU Neuroscience to assess these same measures in animal models.
Another component of our work is digital health research. We use mobile applications to measure clinical and real-world behaviors and decision-making in healthy populations and those with addiction.
Much of our clinical research is focused on the development of tools to help physicians monitor the effectiveness of treatment for opioid dependence, contend with relapse, and evaluate patients’ clinical status.
Neuroeconomic Investigation of Craving in Opioid Addiction
We are evaluating brain function in patients at NYC Health + Hospitals/Bellevue using fMRI brain scans at the beginning and end of six months of treatment for opioid use disorder. Researchers are also investigating patients’ impulsivity and risk-taking behaviors throughout the study period. Our goals are to determine how treatment improves these behaviors, and to assess changes in neurobiology. View additional clinical trial details.
Basic and Translational Research
We conduct both basic and translational research. For example, our research team has developed tools in the laboratory for measuring risk attitude and impulsivity and used fMRI in animal models to evaluate the neurobiological basis of these behaviors. Our scientists have also conducted landmark studies using fMRI to elucidate the role of dopamine in addiction and decision-making.
Ongoing projects include the following.
Neural Mechanisms of Cost and Benefit Integration During Decision-Making
Scientists are conducting a series of fMRI assessments in humans as well as single-unit recording and muscimol inactivation experiments in monkeys to evaluate the neural activity involved in weighing costs and benefits during decision-making. The goal is to test whether separate anterior areas of the brain maintain different representations of costs and benefits.
Adaptation in Decision Circuits: Temporal History and the Efficiency of Choice
Researchers are using electrophysiological recording, computational modeling, and choice behavior experiments in humans and animals to assess how the brain represents subjective value and how these representations adapt over time. This study may one day have implications in depression and bipolar disorder, illnesses that are characterized by periods of low- and high-reward states.
Our research is funded by the National Institutes of Health.
National Institute on Drug Abuse
National Institute of Mental Health
The Glimcher Lab offers research training to graduate and postgraduate students from around the world and is open to fellows who are pursuing an MD/PhD at NYU Grossman School of Medicine. Dr. Glimcher has served as faculty on National Institute on Drug Abuse and National Institute of Mental Health training grants.
Our faculty are experts in decision-making and reward research.
For more information about our research, please contact Ruby Chen, assistant and lab manager, at firstname.lastname@example.org.
Faculty in the decision-making and reward research program publish frequently in peer-reviewed journals. Here is a selection of our recent publications.
Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis
Addiction. 2021 Dec ; 116:3444-3453
Optimizing opioid use disorder treatment with naltrexone or buprenorphine
Drug & alcohol dependence. 2021 Nov 01; 228:?-?
Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial
Alcoholism: clinical & experimental research. 2021 Oct 26;
Quantifying the subjective cost of self-control in humans
Proceedings of the National Academy of Sciences of the United States of America (PNAS). 2021 Aug 31; 118:
Corrigendum to "Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse" [Journal of Substance Abuse Treatment 131 (2021) 108447]
Journal of substance abuse treatment. 2021 Aug 05; 108566
Reductions in tobacco use in naltrexone, relative to buprenorphine-maintained individuals with opioid use disorder: Secondary analysis from the National Drug Abuse Treatment Clinical Trials Network
Journal of substance abuse treatment. 2021 May 21; 130:108489
Comparison of Methods for Alcohol and Drug Screening in Primary Care Clinics
JAMA network open. 2021 May 03; 4:e2110721
Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failure
Journal of substance abuse treatment. 2021 May ; 124:108292